Hypoactive Sexual Desire Disorder (HSDD) is one of the most common — and most underdiagnosed — sexual health conditions affecting adults today. Despite its clinical name, it describes something millions of people experience and often dismiss as "just getting older" or "being tired." Understanding what HSDD is, what causes it, and what treatment paths exist is the starting point for addressing it.

What Is HSDD?

HSDD is defined in the DSM-5 as a persistent or recurrent deficiency in sexual fantasies and desire for sexual activity that causes marked distress or interpersonal difficulty. The distress component is critical — low desire alone is not HSDD. Low desire that bothers you or affects your relationship is the clinical threshold.

In women, the related DSM-5 category is Female Sexual Interest/Arousal Disorder (FSIAD), though HSDD remains the commonly used clinical and research term. In men, it appears as Male Hypoactive Sexual Desire Disorder.

How Common Is HSDD?

Population	Estimated Prevalence	Most Common Age Range	Key Driver
Pre-menopausal women	8–10%	30s–40s	Stress, hormonal contraception, relationship factors
Peri/post-menopausal women	12–15%	45–60	Estrogen decline, testosterone drop, cortisol elevation
Men under 50	5–15%	40s	Testosterone decline, stress, antidepressants
Men over 60	20–40%	60s–70s	Age-related testosterone decline

What Causes HSDD?

HSDD is not a single-cause condition. Research identifies a cluster of drivers that interact, and most cases involve more than one simultaneously (PMID 30909007).

1. Hormonal imbalance. In women, low estrogen (particularly post-menopause) and low free testosterone are the most common hormonal drivers. In men, declining free testosterone — which begins at approximately 1–2% per year after age 30 — is the primary factor. DHEA, a precursor to both estrogen and testosterone, also declines with age and stress (PMID 30909007).
2. Chronic cortisol elevation. The HPA (hypothalamic-pituitary-adrenal) axis and HPG (hypothalamic-pituitary-gonadal) axis directly compete. When the stress response is chronically activated, glucocorticoids suppress gonadotropin-releasing hormone (GnRH), which cascades into lower LH and testosterone/estrogen production (PMID 24064362). Prolonged work stress, caregiving load, or sleep deprivation can sustain this suppression indefinitely.
3. Medication side effects. SSRIs and SNRIs (antidepressants) are the most common pharmaceutical cause of acquired HSDD — affecting 30–40% of patients on these medications. Combined oral contraceptives with ethinyl estradiol can reduce free testosterone by elevating SHBG, a binding protein that makes testosterone unavailable for sexual function (PMID 16409223).
4. Relationship and psychological factors. HSDD can be situational (low desire with one partner but not another) or generalized. Chronic relationship conflict, emotional disconnection, or unresolved sexual trauma can maintain HSDD independent of hormonal status (PMID 23841462).
5. Physical health conditions. Diabetes, thyroid disorders, anemia, and chronic pain all correlate with reduced sexual desire. These work through overlapping pathways — energy availability, vascular health, and hormonal signaling all affect desire capacity.

How Is HSDD Diagnosed?

There is no blood test for HSDD. Diagnosis is clinical — a prescriber takes a sexual history, reviews medications, checks for comorbid conditions, and uses validated instruments like the FSFI (Female Sexual Function Index) or IIEF (International Index of Erectile Function) to quantify the degree of dysfunction.

The key diagnostic questions are duration (must be persistent, not brief and situational), level of distress (must cause personal distress or relationship difficulty), and whether the presentation is better explained by another diagnosis, relationship problem, or drug effect.

Treatment Options: From Prescription to Non-Prescription Support

Prescription options for HSDD include flibanserin (Addyi) for premenopausal women, bremelanotide (Vyleesi) for premenopausal women, and testosterone therapy for postmenopausal women in some clinical contexts. All require prescriber involvement.

Non-prescription approaches with clinical support include botanical supplements targeting the same pathways. Tribulus Terrestris has been shown to support LH signaling and reduce SHBG effects in multiple trials (PMID 40219032). Muira Puama has a documented track record in HSDD-adjacent conditions dating to the Waynberg 1990 study (PMID 11186145). These botanicals support the hormonal and neural environment that healthy desire depends on — they are not clinical treatments for diagnosed HSDD.

If you're experiencing low desire that's distressing you or affecting your relationship, a conversation with a prescriber is the right first step. NUUD's libido supplement formulas are designed for the broader population of people experiencing reduced desire who prefer non-prescription botanical support. Learn more about NUUD libido supplements.

Frequently Asked Questions

What is the difference between low libido and HSDD?

Low libido means reduced sexual desire. HSDD means low sexual desire that causes personal distress or relationship difficulty. The distress criterion is everything — many people have naturally low desire and are unbothered by it. That's not HSDD.

Can HSDD go away on its own?

Yes — particularly when the cause is temporary (a stressful life period, a medication change, postpartum hormonal shifts). Acquired HSDD tends to have more identifiable triggers and better treatment response than lifelong HSDD.

Is HSDD more common in women than men?

Diagnosed more frequently in women — partly because women seek care more often, partly because clinical criteria were originally developed with women in mind. Male HSDD is underdiagnosed. Estimates suggest it affects 5–15% of men under 50 and up to 40% of men over 60.

Do libido supplements treat HSDD?

Botanical libido supplements are not approved as treatments for HSDD. They support the hormonal and neural environment underlying healthy desire — specifically through LH-signaling support (Tribulus), nerve-ending sensitivity (Muira Puama), and adaptogenic stress modulation (Mushroom Complex). They are appropriate for people seeking non-prescription support, not as a clinical HSDD treatment.

What is the fastest way to address HSDD?

Identify and address the primary driver. If it's a medication side effect — talk to your prescriber about alternatives. If it's relationship conflict — therapy is more effective than any supplement. If it's chronic stress and hormonal baseline — lifestyle changes combined with botanical support address the physiological layer. Prescription options exist for cases where these don't resolve it.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.